Skip to content

Comparison Of INIT Versus NMR in Patients With Deep Gluteal Syndrome

Comparison Of Integrated Neuromuscular Inhibition Technique Versus Neuromuscular Reeducation in Patients With Deep Gluteal Syndrome

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06197516
Enrollment
54
Registered
2024-01-09
Start date
2023-04-10
Completion date
2023-11-15
Last updated
2024-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Gluteal Syndrome

Keywords

Trigger point, NMR, INIT, Deep Gluteal Syndrome

Brief summary

Rationale of this research is to evaluate the outcome of Comparison of Integrated Neuromuscular Inhibition technique versus Neuromuscular reeducation on pain in patients with Deep Gluteal Syndrome. The significance of this study is to identify which technique is superior in alleviating the symptoms of deep gluteal syndrome. This study will help gather evidence on the practice of incorporating trigger point therapy in the treatment of deep gluteal syndrome.

Detailed description

Deep gluteal syndrome is a common buttock and posterior hip pain caused by entrapment of the sciatic nerve in the posterior hip region. Nonoperative therapy involves treating the entrapment location, using rest, anti-inflammatories, musclerelaxants, and physical therapy to relieve compression. The purpose of the study was to evaluate the effects of Integrated Neuromuscular Inhibition Technique versus Neuromuscular Reeducation Technique on pain in subject with deep gluteal syndrome. It was a randomized, controlled trial, conducted among deep gluteal syndrome patients. Sample size was 54 by using G Power Tool software. Participantswere randomly assigned to the intervention or control group after a baseline assessment with a lottery ticket and an opaque envelope. All participants in both groups were evaluated on baseline and 12 th Session.

Interventions

OTHERIntegrated Neuromuscular Inhibition Technique

After palpating the trigger point ischemic compression were applied for 20-60 sec while strain Counterstain for 60-90 sec and MET is for 7-10 sec.

Deep pressure were applied along origin and insertion of Piriformis and hamstring muscle combined with active movement of patient for 5 -15 time as per required

Sponsors

Riphah International University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
30 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

Both genders Age: 30-50 years Pain due to a non-discogenic sciatic nerve entrapment in the sub gluteal space Pain, tightness and dysesthesias in the buttock area, posterior thigh Buttock pain aggravated with prolong sitting (>20-30 min) Buttock pain aggravated when sitting with limited straight leg raising ability (seated piriformis test) Pain with the passive internal rotation of hip (Freiberg sign) Pain increase in Flexion, Adduction and internal rotation (Positive FAIR test)

Exclusion criteria

* Patient with any Intrinsic Etiology such as hemarthrosis, rheumatoid arthritis, infection or gout Patient with any severe trauma, fractures dislocation, subluxation or ligament injury Any pathology or recent injury around the hip, sacroiliac joint, or lumbar spine Limb length discrepancy Recent buttock trauma and bladder/bowel dysfunction

Design outcomes

Primary

MeasureTime frameDescription
NPRS4th weekNumeric Pain Rate Scale used to assess pain intensity
Goniometer4th weekused to assess lower limb ranges
Lower Extremity Functional scale4th weekLEFS questionnaire have 20 questions will assess the impairment of a patient with lower extremity musculoskeletal condition or disorders
Sciatica Bothersomeness Index4th weekused to measure the participants' level of sciatica. The scale's ratings range from 0 to 24, with higher levels indicating severe sciatica discomfort.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026